Fact checked by Nick Blackmer Eli Lilly decreased the prices of Zepbound and introduced higher-dose options to make the ...

Hims & Hers (NYSE:HIMS) fell ~8% in the premarket Thursday after a federal judge denied a motion filed by a compounding trade group over the FDA’s decision to declare that Eli Lilly’s (NYSE:LLY) ...

Eli Lilly is suing two pharmacies for compounding Zepbound and Mounjaro, claiming the companies are skirting the Food and Drug Administration's ban on the practice and luring people away from ...

(Reuters) — Novo Nordisk and Eli Lilly denied weight-loss drug partnership with Mangoceuticals on Thursday, hours after the telehealth provider disclosed it had arrangements with the two ...

(Reuters) -Novo Nordisk and Eli Lilly denied weight-loss drug partnership with Mangoceuticals on Thursday, hours after the telehealth provider disclosed it had arrangements with the two ...

In an early human trial, Eli Lilly's eloralintide helped people lose up to 20% of their body weight. Reading time 3 minutes The race to develop the next generation of weight loss drugs has ...

CNN’s Erin Burnett talks to Eli Lilly CEO David Ricks about the company’s anticipated weight loss pill, its affordability, and the potential jobs created from a new $6 billion U.S. factory.

Women with polycystic ovary syndrome are increasingly turning to blockbuster weight-loss drugs from Eli Lilly and Novo ...